全文获取类型
收费全文 | 6492篇 |
免费 | 351篇 |
国内免费 | 28篇 |
专业分类
耳鼻咽喉 | 43篇 |
儿科学 | 168篇 |
妇产科学 | 92篇 |
基础医学 | 923篇 |
口腔科学 | 223篇 |
临床医学 | 414篇 |
内科学 | 1455篇 |
皮肤病学 | 213篇 |
神经病学 | 810篇 |
特种医学 | 170篇 |
外科学 | 526篇 |
综合类 | 29篇 |
现状与发展 | 1篇 |
预防医学 | 358篇 |
眼科学 | 272篇 |
药学 | 553篇 |
中国医学 | 16篇 |
肿瘤学 | 605篇 |
出版年
2024年 | 8篇 |
2023年 | 54篇 |
2022年 | 116篇 |
2021年 | 171篇 |
2020年 | 104篇 |
2019年 | 141篇 |
2018年 | 148篇 |
2017年 | 127篇 |
2016年 | 171篇 |
2015年 | 176篇 |
2014年 | 219篇 |
2013年 | 257篇 |
2012年 | 464篇 |
2011年 | 544篇 |
2010年 | 300篇 |
2009年 | 220篇 |
2008年 | 431篇 |
2007年 | 456篇 |
2006年 | 440篇 |
2005年 | 452篇 |
2004年 | 444篇 |
2003年 | 411篇 |
2002年 | 398篇 |
2001年 | 35篇 |
2000年 | 34篇 |
1999年 | 48篇 |
1998年 | 68篇 |
1997年 | 42篇 |
1996年 | 55篇 |
1995年 | 41篇 |
1994年 | 33篇 |
1993年 | 28篇 |
1992年 | 23篇 |
1991年 | 27篇 |
1990年 | 24篇 |
1989年 | 16篇 |
1988年 | 17篇 |
1987年 | 16篇 |
1986年 | 9篇 |
1985年 | 12篇 |
1984年 | 13篇 |
1983年 | 5篇 |
1982年 | 16篇 |
1981年 | 10篇 |
1980年 | 16篇 |
1979年 | 3篇 |
1978年 | 4篇 |
1977年 | 5篇 |
1975年 | 3篇 |
1974年 | 5篇 |
排序方式: 共有6871条查询结果,搜索用时 15 毫秒
131.
132.
133.
Takahiro Ando Hidenori Kage Yoko Matsumoto Koichi Zokumasu Takuma Yotsumoto Keita Maemura Yosuke Amano Kousuke Watanabe Jun Nakajima Takahide Nagase Daiya Takai 《Cancer science》2020,111(1):200-208
Integrins are transmembrane proteins that mediate cell adhesion to the extracellular matrix. Integrin α11 (ITGA11) is not expressed in normal alveolar epithelial cells and is a known receptor for collagen. While integrin α11β1 overexpression in the tumor stroma has been associated with tumor growth and metastatic potential of non–small cell lung cancer (NSCLC), little is known about the role of ITGA11 in tumor cells. Thus, we examined the RNA expression of ITGA11 by quantitative RT‐PCR in 80 samples collected from NSCLC patients who had undergone surgical resection and analyzed the clinical outcomes. We found that high expression of ITGA11 was associated with lower recurrence‐free survival in all NSCLC patients (P = 0.043) and in stage I NSCLC patients (P = 0.049). These results were consistent with in silico analyses of the Cancer Genome Atlas database. We also analyzed cell proliferation, migration and invasion capacity in lung cancer cell lines after overexpression of ITGA11. Overexpression of ITGA11 in lung cancer cell lines had little effect on cell proliferation but resulted in increased migration and invasion capacity. Our findings suggest that ITGA11 plays a significant role in cancer migration and invasion, leading to higher recurrence. ITGA11 expression may be a predictor of poor prognosis in patients with surgically resected NSCLC. 相似文献
134.
135.
Eiji Kawasaki Takahiro Fukuyama Aira Uchida Yoko Sagara Yuko Nakano Hidekazu Tamai Masayuki Tojikubo Yuji Hiromatsu Nobuhiko Koga 《Journal of diabetes investigation.》2022,13(4):738
Interleukin‐6 is a pleiotropic cytokine that plays a pathogenic role in type 1 diabetes. Therefore, anti‐interleukin‐6 receptor antibody, tocilizumab, used for the treatment of rheumatoid arthritis, is considered a candidate for immune intervention in type 1 diabetes. Here, we report the case of a 73‐year‐old woman (HLA‐DR9‐DQ3 homozygote) with well‐controlled rheumatoid arthritis who developed type 1 diabetes while receiving tocilizumab treatment. At 57 years‐of‐age, the patient was diagnosed with rheumatoid arthritis, for which she underwent tocilizumab therapy that enabled complete suppression of her joint inflammation. A total of 17 months after starting tocilizumab therapy, she noticed polydipsia, polyuria, general fatigue and weight reduction (−2 kg/month), and was diagnosed with type 1 diabetes with diabetic ketoacidosis based on an arterial pH of 7.26, serum ketone body of 7,437 μmol/L, blood glucose level of 925 mg/dL, glycated hemoglobin of 13.2% and the presence of anti‐islet autoantibodies. This case report shows valuable insight regarding the effect of anti‐interleukin‐6 receptor antibody therapy on type 1 diabetes prevention. 相似文献
136.
Takahito Ito Ryo Ogawa Akiyoshi Uezumi Takuji Ohtani Yoko Watanabe Kazutake Tsujikawa Yuko Miyagoe-Suzuki Shin’ichi Takeda Hiroshi Yamamoto So-ichiro Fukada 《Neuromuscular disorders : NMD》2013,23(4):349-356
Imatinib mesylate inhibits signaling of tyrosine kinase receptors, including PDGFRα, and has been used for human cancer therapy. Recent studies have indicated that imatinib is also effective in treatment of some chronic diseases with fibrosis. Fibrosis is the feature of Duchenne muscular dystrophy. It has been reported that imatinib attenuates fibrosis in mdx mice. Recently we revealed that PDGFRα is specifically expressed in muscle mesenchymal progenitors, which are the origin of muscle fibrosis. Here, we show that imatinib ameliorates the muscular pathology of DBA/2-mdx, a more severe mouse muscular dystrophy. In addition, imatinib inhibits both the proliferation and fibrosis marker expression induced by PDGF-AA in muscle mesenchymal progenitors in vitro. Importantly, the effective dose of imatinib on muscle mesenchymal progenitors did not inhibit myoblast proliferation. These results suggest that imatinib targets mesenchymal progenitors, and that a therapeutic strategy targeting mesenchymal progenitors could be a potential treatment for muscular dystrophies. 相似文献
137.
Perihepatic lymph node enlargement observed at a general health examination: A cross‐sectional study
138.
Yasufumi Masaki Hiroshi Kawabata Kazue Takai Masaru Kojima Norifumi Tsukamoto Yasuhito Ishigaki Nozomu Kurose Makoto Ide Jun Murakami Kenji Nara Hiroshi Yamamoto Yoko Ozawa Hidekazu Takahashi Katsuhiro Miura Tsutomu Miyauchi Shinichirou Yoshida Akihito Momoi Nobuyasu Awano Soichiro Ikushima Yasunori Ohta Natsue Furuta Shino Fujimoto Haruka Kawanami Tomoyuki Sakai Takafumi Kawanami Yoshimasa Fujita Toshihiro Fukushima Shigeo Nakamura Tomohiro Kinoshita Sadao Aoki 《International journal of hematology》2016,103(6):686-692
139.
Atsuko Yokomatsu Tetsuya Fujikawa Yoshiyuki Toya Midori Shino‐Kakimoto Yoko Itoh Hiroshi Mitsuhashi Kouichi Tamura Nobuhito Hirawa Gen Yasuda Satoshi Umemura 《Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy》2014,18(4):340-346
During hemodialysis, amino acid loss through the dialysate remained a significant problem and was not clear in some dialyzers; therefore, we investigated amino acid loss with hydrophilic and nonhydrophilic polyester–polymer alloy membranes and polyacrylonitrile membranes. Nine maintenance hemodialysis patients were studied to assess amino acid loss during hemodialysis with the three membranes. Total amino acid losses were 85.7 ± 27.2 mg/L, 83.3 ± 16.1 mg/L, and 72.1 ± 22.5 mg/L with the hydrophilic, nonhydrophilic polyester–polymer alloy, and polyacrylonitrile membranes, respectively. Amino acid losses were greater with the hydrophilic membrane compared with the polyacrylonitrile membrane for ornithine (2.0 ± 0.6 vs. 1.4 ± 0.4 mg/L, P = 0.025), phenylalanine (2.4 ± 0.9 vs. 1.8 ± 0.8 mg/L, P = 0.012), and tryptophan (0.6 ± 0.2 vs. 0.4 ± 0.2 mg/L, P = 0.023). Amino acid losses were greater with the nonhydrophilic membrane than with the polyacrylonitrile membrane for ornithine (2.0 ± 0.4 vs. 1.4 ± 0.4 mg/L, P = 0.017), phenylalanine (2.3 ± 0.5 vs. 1.8 ± 0.8 mg/L, P = 0.018), tryptophan (0.7 ± 0.2 vs. 0.4 ± 0.2 mg/L, P = 0.003), and cystine (3.2 ± 0.7 vs. 2.0 ± 0.7 mg/L, P = 0.005). In conclusion, greater losses of ornithine, phenylalanine, tryptophan, and cystine were observed with polyester–polymer alloy than with polyacrylonitrile membranes during hemodialysis. Constant attention should be paid to the amino acid loss profile to improve nutritional control in hemodialysis patients. 相似文献
140.
Yamashita H Ohno K Amada Y Hattori H Ozawa-Funatsu Y Toya T Inami H Shishikura J Sakamoto S Okada M Yamaguchi T 《The Journal of pharmacology and experimental therapeutics》2004,308(1):127-133
The anticonvulsant activity of 2-[N-(4-chlorophenyl)-N-methylamino]-4H-pyrido[3.2-e]-1,3-thiazin-4-one (YM928), a novel alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist, was studied in animal models of generalized seizure. YM928 exerted significant anticonvulsant effects in the maximal electroshock (MES) seizure test (ED50 = 7.4 mg/kg p.o.), pentylenetetrazol (PTZ)-induced seizure test (ED50 = 9.6 mg/kg p.o.), AMPA-induced seizure test (ED50 = 5.5 mg/kg p.o.), and strychnine-induced seizure test (ED50 = 14.0 mg/kg p.o.) in mice. Effects in rats were detected in the MES seizure test (ED50 = 4.0 mg/kg p.o.) and PTZ-induced seizure test (ED50 = 6.2 mg/kg p.o.). The profile of YM928 was compared with that of established antiepileptics. Valproate showed beneficial effects in all tests used. In contrast, carbamazepine, phenytoin, lamotrigine, phenobarbital, diazepam, ethosuximide, and gabapentin were not active against seizures induced by at least one stimulant. In the rotarod test, YM928 impaired motor coordination (TD50 = 22.5 mg/kg p.o.). The protective index (TD50 value of the rotarod test/ED50 value of MES seizure) was 3.0, suggesting that YM928 can exert antiepileptic effects with only minor motor disturbances. YM928 at doses of 2, 4, and 8 mg/kg p.o. did not significantly affect the threshold of electroshock seizure in rats after 16 days of repeated administration. These data indicate that YM928 does not induce tolerance after subchronic administration. These results indicate that YM928 is a broad-spectrum anticonvulsant that would prove useful for the treatment of generalized seizure in human epileptic patients. 相似文献